Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration
|
|
- Roy Jefferson
- 6 years ago
- Views:
Transcription
1 Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration Marilita M. Moschos Abstract- Purpose: To evaluate by OCT and mf-erg the macular function in eyes with CNV due to ARMD before and after intravitreal use of bevacizumab and ranibizumab. Methods: Eighteen eyes with subfoveal CNV due to ARMD were studied before and after intravitreal use of bevacizumab with MFERG and OCT. The post follow up was three months. Also fifteen eyes with CNV due to ARMD were studied with OCT and mferg before, during and at the end of the, a year after the first injection of ranibizumab. Results: Three months after with bevacizumab, OCT showed a real resolution of the subretinal fluid. The electrical responses in the fovea and parafovea remained the same or slightly improved in some cases. After the use of ranibizumab visual acuity increases significantly by time (p=0.005). A borderline negative association between foveal thickness and time with decrease of the mean foveal thickness for one time increment was found. The retinal response density of mferg show a significant increase in ring 1, remained almost unchanged in ring 2, whereas in ring 3 there is some evidence of increase not statistically significant. Conclusion: The intravitreal use of bevacizumab may provide anatomical correlates that support the concept of disease amelioration but the functional improvement of the macula three months after is not obvious. The intravitreal use of ranibizumab may provide some anatomical and electrophysiological amelioration of the macula. However, randomized long-term clinical trials are needed to determine the potential clinical benefit of bevacizumb and ranibizumab. Keywords: Age related macular degeneration (ARMD), bevacizumab (Avastin), ranibizumab, multifocal Electroretinogram (MFERG), Optical Coherence Tomography (OCT). I. INTRODUCTION Choroidal neovascularisation (CNV) is a leading cause of loss of central vision in developed countries.[1] The neovascularisation is originated from the choroidal blood vessels and grows through Bruch s membrane usually at multiple sites into the sub-retinal pigmented epithelial space and disrupts the anatomy of the retinal pigment epithelium photoreceptors complex.[2,3,4] The important role of the vascular endothelial growth factor (VEGF) in the pathogenesis of exudative ARMD has been documented in many studies [5,6,7] and new therapeutic strategies consider the application of VEGFbinding substances to reduce the activity of VEGF and thus to prevent progression of exudative ARMD. Bevacizumab binds all biologically active forms of VEGF, as ranibizumab does. It is currently approved for use in humans but is labeled for cancer [7]. In our study we offered offlabel intravitreal use of bevacizumab to patients with CNV due to ARMD not expected to respond to conventional methods of [8]. The aim of our nonrandomized prospective study was to 190
2 record the electroretinographic changes of the foveal, parafoveal and perifoveal area by means of mferg [9] in eyes with subfoveal CNV concurrently with OCT changes before and after intravitreal use of bevacizumab of ranibizumab and to assess objectively its efficacy. II. MATERIALS and METHODS We studied 2 groups of patients Group A includes 18 eyes of 18 consecutive patients with CNV secondary to ARMD treated with off-label intravitreal bevacizumab. All eyes had large occult or minimally classic lesions. In these cases no benefit would be expected by using any alternative method of. The study protocol was approved by the local institutional review board of our hospital and all the patients signed a written consent statement particularly in the regard to the offlabel use of intravitreal use of bevacizumab. The mean age of the patients was years (range 52-84), (SD 8.31) (Table 1). Ten patients were males and eight females. Best corrected visual acuity was measured by means of standard Snellen chart at baseline, 1 month and 3 months after. The procedure was carried out in the operation theatre. Topical proparacaine hydrochloride 0.5% was applied to the ocular surface followed by preparation with 5% povidone iodine. Visual acuity and MFERG monitored the functional response to. The anatomical improvement was assessed by OCT central macular thickness measurement at 1 and 3 months after in injection. Group B includes 15 patients (15 eyes) with CNV due to ARMD were treated with intravitreal use of ranibizumab. All eyes had predominantly classic, minimal classic or occult CNV. Nine patients were female and six male with a mean age of 70.6 (SD 5.94). All eyes were injected monthly for the first 3 months, followed by doses every three months for a year with 0.3 mg of intravitreal ranibizumab. Thus during the 12-months study, a total of six ranibizumab injections were given. Intravitreal injection procedure has been described previously.[16] On presentation all patients underwent a complete ophthalmic examination, including measurement of best corrected visual acuity, fundus examination, intraocular pressure measurement, fluorescein angiography, OCT scan and mf-erg recording. At subsequent injection visits, subjects underwent a preinjection safety evaluation. OCT and mf-erg assessment was evaluated at the 1st, 3rd, 6th, 9th and 12th month after the first injection of ranibizumab. Best corrected visual acuity was measured by means of LogMar equivalent at baseline, 1, 3, 6, 9 and 12 months after the first injection of ranibizumab. Optical Coherence Tomography (OCT) OCT examination was performed with the OCT model (Carl Zeiss Meditec, Stratus OCT). The retinal mapping software was used, calculating the averaged retinal thickness of the central ring. All eyes were scanned in a radial spoke pattern centered on the foveola with scan length of 6mm. Multifocal-ERG For the recording of the mf-erg, the EP model (Tomey, Nagoya, Japan) was used and the recording protocol followed was according to the ISCEV guidelines for basic mf-erg. Statistical analysis Quartiles, mean and standard deviation were calculated in each time period in order to describe the distribution of amplitude, latency, foveal thickness and visual acuity. Linear mixed effects models were used to analyze the data. Differences in longitudinal amplitude and latency data over time were evaluated among foveal (ring1), parafoveal (ring 2) and perifoveal (ring 3) area. The interaction term (type of ring*time) was included to consider differential effects in the rate of change over time in each ring. Foveal thickness and visual acuity were measured only in the foveal area (ring 1). Kolmogorov- 191
3 Smirnov test evaluated the assumption of normality. We tested for quadratic term of time, but it was not found significant in none of the statistical models. Restricted likelihood (REML) was used for maximization. All statistical tests were two sided; p-value<0.05 was considered statistically significant. The analyses were conducted with Stata statistical software (version 10) and graphs with MLwiN. III. RESULTS Table 1 shows the changes of VA during the 3 months follow-up period after the injection with bevacizumab. No significant difference was found between VA at baseline and 3 months after (P=0.2261) (Table 1). Table 2 shows the changes of foveal thickness during the 3 months follow-up period after with bevacizumab. Statistical analysis revealed an extremely significant difference between foveal thickness at baseline and 1 month after (P<0.001). No difference was found 3 months after (P=0.0592). It is interesting that 3 months after, in 8 cases the foveal thickness (case no 1, 9, 10, 11, 12, 14, 15, 16 and 17) was lower than before, in 4 cases (case no 5, 8, 13 and 18) was higher and in the remaining 5 cases (case no 2, 3, 4, 6 and 7) remained almost unchanged. Concerning the mf-erg changes in area 1 no difference was found between baseline and 3 months (P=0.1285) (Table 2). Statistical analysis revealed a very significant difference between retinal response density of area 2 at baseline and 1 month after (P<0.01). This difference remained significant 3 months after (P<0.05) (Table 2 and Fig 1). It should be stressed that 3 months after, the retinal response density of area 1 improved more than 1nV/deg² in 8 cases (case no 4, 5, 9, 10, 13, 15 and 17), decreased in 2 cases (case no 8 and 12) and remained almost stable in the remaining 8 cases. The retinal response density of area 2 recorded by MFERG improved of more than 1nV/deg² in 4 cases (case no 3, 5, 7 and 8) and remained almost unchanged in the remaining 14 cases. On the other hand a total of 15 patients (15 eyes) treated with ranibizumab were included in the study. Figure 2 shows graphical presentations of the mean values of retinal response density (Figure 2A), latency (Figure 2B), foveal thickness (Figure 2C) and VA (Figure 2D) in each time measurement (Figure 3, 4). Several models of the linear mixed effects analysis are presented in Table 3. In Model 1 retinal response density was considered as the outcome variable whereas time and ring as the explanatory ones. There was a highly significant interaction between ring and time, indicating differences in the rate of change of amplitude over time among the three rings. Specifically, one time unit increase was found to increase significantly the mean retinal response density in ring1 by 5.13 nv/deg 2 (95% CI: 2.45, 7.80). However, mean retinal response density remained almost unchanged over time in ring 2, whereas for ring 3, there was some evidence for increase over time but the result was of borderline significance (p=0.063). In Model 2 latency was the outcome variable whereas time and ring the explanatory variables. At baseline measurement the mean levels of latency were not found to differ significantly among ring 1, ring 2 and ring 3. Time did not seem to have any effect in latency levels with mean latency remaining almost unchanged throughout the twelve months of the period in all the three rings. With respect to foveal thickness which was measured by OCT, the linear mixed effects analysis (Model 3, Table 3) showed a borderline inverse association between foveal thickness and time (p=0.065) with a decrease of mean foveal thickness by 8.46 µm (95% CI: , 0.52) for one time unit increase. Lastly, according to Model 4 (Table 3), a highly significant time effect was identified, with mean visual acuity increasing significantly by time (p=0.005). 192
4 Concerning retinal response density, its significant positive association with time remained. Amplitude was not found to be associated with foveal thickness (p=0.887) whereas a borderline positive association was identified between amplitude and visual acuity (OR: , 95% CI: , 0.63). Concerning latency, its relationship with time remained statistically non-significant even after adjustment for foveal thickness and visual acuity. Foveal thickness and visual acuity seemed to be unrelated to latency. Visual acuity, after adjustment for foveal thickness, increased significantly by time. However foveal thickness was not found to be associated with visual acuity (p=0.482). IV. DISCUSSION The of choroidal neovasularization in ARMD has changed enormously during the last decade. While 10 years there was only Argon laser coagulation and later photodynamic therapy with verteporfin, today we have several options for CNV.[1] Results from PIER study indicate that ranibizumab administered on a schedule of monthly dosing for three months followed by quarterly dosing provides significant visual acuity benefit to patients with all angiographic subtypes of CNV. Unfortunately, there are no data available at six and nine months to allow assessment of duration of action of ranibizumab in the individual subjects and the temporal association with retinal thickness. In this retrospective study 18 eyes with CNV due to ARMD were treated with intravitreal bevacizumab. Our results show that there are anatomical correlates to support the concept of disease improvement. This is mainly the decrease of macular thickness as measured by OCT in an extremely significant degree (P<0.001) the first month after. On the contrary the mean visual acuity improved only by 0.03 the first month after and by 0.02 three months after. Also the MFERG improvement did not follow the decrease of macular thickness and is significant the first month after (P<0.05). However MFERG results, three months after, show a little rise of the electrical activity of area 2 (P<0.05), which may be attributed to the decrease of the macular edema more than to the improvement of the macular function [9, 10]. Our results from the intravitreal use of ranibizumab show a significant increase of the visual acuity and the retinal response density of the foveal area (ring1) during, whereas in ring 2 and 3 the retinal response density remained almost unchanged. Also, the latency remained unchanged during. Concerning with the foveal thickness a borderline non statistically significant decrease was identified. Finally, visual acuity and retinal response density of the foveal area seemed to be unrelated with foveal thickness. This may be explained by the fact that the macular edema is only a parameter that may affect visual acuity and the electrical activity of the macula. Consequently, increase or decrease of macular thickness does not necessarily reflect the course of the visual acuity as supported.[11] Atrophy of the retina, particularly of the photoreceptors, atrophy of the pigment epithelium and scarring are all unmeasured parameters which influence vision. While anti-vegf s are revolutionary, the frequency of use of the drugs still needs to be determined. Two previous studies investigated the effects of anti-vegf (bevacizumab) on retinal function by means of mf-erg in ARMD patients before and after intravitreal use of bevacizumab.[10] They found that neuroretinal function did not change in most of the patients compared to baseline values. Feigl s preliminary results in a small number of patients receiving ranibizumab confirm the above mentioned studies.[12] However we consider that randomized longterm clinical trials are needed to determine more accurately the potential clinical benefit of intravitreal anti-vegf. REFERENCES 193
5 1. Kroll P, Meyer CH (2006) Which is best for AMD patients. Br J Ophthalmol. 90: Chang TS, Freund KB, de la Cruz Z, Yannouzi LA, Green WR (1994) Clinicopathological correlation of choroidal neovascularization demonstrated by indocyanine green angiography in a patient with retention of good vision for almost four years. Retina. 14: Green WR, Wilson DJ (1996) Choroidal neovascularisation. Ophthalmology. 93: Green WR, Ehger C (1993) Age related macular degeneration histopathologic studies. The 1992 Lorenz E. Zimmerman Lecture. Ophthalmology. 100: Ambati J, Ambati BK, Yoo SH, Lanchulev S, Adamis AP (2003) Agerelated macular degeneration: etiology, pathogenesis and therapeutic strategies. Surv Ophthalmol. 48: Zarbin MA (2004) Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 122: Adamis AP, Shima DT (2005) The role of vascular endothelial growth factor in ocular health and disease. Retina. 25: Avery RL, Pieramici DJ, Rabena MD et al (2006) Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 113: e5. 9. Sutter EE, Tram D (1992) The field topography of ERG components in man. I. The photopic luminance response. VBision res. 32: Moschos MM, Brouzas D, Apostolopoulos M, Koutsandrea Chr, 11. Loukianou E, Moschos M (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal ERG and OCT study. Doc Ophthalmologica. 114: Lipski A, Bornfeld N, Jurklies B (2007) Multifocal electroretinography in patients with exudative AMD and intravitreal with pegaptamib sodium. Retina. 27: Feigl B, Greaves A, Brown B (2007) Functional outcome after multiple s with ranibizumab in neovascular age-related macular degeneration beyond visual acuity. Clin Ophtalmology
6 Table 1. Clinical data of patients with CNV due to ARMD before, 1 and 3 months after with bevacizumab. No Age VA* before VA* 1 month after Mean value SD *Visual VA* 3 months after acuity 195
7 Table 2. OCT and MFERG recordings of area 1 and 2 before, 1 month and 3 months after with bevacizumab. The mean foveal thickness measured by OCT is expressed in µm. The retinal response densities measured by MFERG are expressed in nv/deg². No Before 1 month after 3 months after Before 1 month after 3 months after OCT OCT OCT Area 1 Area 2 Area 1 Area 2 Area 1 Area Average STDEV
8 Figure 2. Mean values in the foveal area (ring 1) in each time measurement* for: (A) amplitude of mfvep, (B) latency of mfvep, (C) foveal thickness, and (D) visual acuity of patients treated with ranibizumab Figure A Figure B Figure C Figure D *Time measurement: 1: baseline 2: 1 month after first 3: 3 months after first 4: 6 months after first 5: 9 months after first 6: 12 months after first 197
9 Table 3: Linear mixed effects analysis for the association between over time and amplitude (Model 1), latency (Model 2), foveal thickness (Model 3) and visual acuity (Model 4) of patients treated with ranibizumab Category or Increment Coefficient 95% CI P-value Model 1: Amplitude Intercept Ring (88.41, ) - Ring (60.81, 91.98) Ring (36.69, 67.86) < Time 1 time unit increase in Ring (2.45, 7.80) - 1 time unit increase in Ring (-2.17, 3.17) time unit increase in Ring (-0.78, 4.57) Model 2: Latency Intercept Ring (40.29, 44.99) - Ring (38.68, 43.38) Ring (39.36, 44.06) Time 1 time unit increase in Ring (-0.38, 0.38) - 1 time unit increase in Ring (-0.55, 0.21) time unit increase in Ring (-0.49, 0.27) Model 3: Foveal thickness Intercept (363.12, ) - Time 1 time unit increase (-17.44, 0.52) Model 4: Visual acuity Intercept 0.23 (0.17, 0.29) - Time 1 time unit increase (-0.009, ) Ring 1 is the reference group. All P-values derived from the comparison of each category with the reference group. 198
10 Proceedings of the World Medical Conference Figure 1. MFERG of case 2, at presentation (A) and 3 months later (B). The 3-dimension topographic plot of MF-ERG 3 months after remains pathological and the ERG traces in area 1 and 2 do not show any amelioration. Figure 3. OCT recordings, 3-dimension topographic plot and mf-erg traces dimension topographic plot of a case at presentation (A), 6 months (B) and 1 year after (C) with ranibizumab. The pre OCT showed an increase of central retinal thickness and mf-erg revealed a decrease of electrical activity of the fovea and perifovea area. At the end of the follow-up period (C) the retinal thickness of the fovea was decreased and the mf-erg was ameliorated. 199
11 Figure 4. OCT recordings, 3-dimension topographic plot and mf-erg traces dimension topographic plot of a case at presentation (A), 6 months (B) and 1 year after (C) with ranibizumab. The pre OCT showed an increase of central retinal thickness and a decrease of electrical activity of the fovea and perifovea area. At the end of the follow-up period (C) the retinal thickness of the fovea was still increased and the mf-erg revealed a craterlike depression of the foveal and parafoveal area.. 200
International Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationA Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact Omesh P. Gupta, MD, MBA, Gary Shienbaum, MD, Avni H. Patel, MD, Christopher Fecarotta,
More informationFocal Macular Electroretinograms after Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration
Retina Focal Macular Electroretinograms after Intravitreal s of Bevacizumab for Age-Related Macular Degeneration Eiji Iwata, Shinji Ueno, Kohei Ishikawa, Yasuki Ito, Ruka Uetani, Chang-Hua Piao, Mineo
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More informationAlthough photocoagulation and photodynamic PROCEEDINGS PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION *
PEGAPTANIB SODIUM FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION Evangelos S. Gragoudas, MD ABSTRACT In December 24, the US Food and Drug Administration (FDA) approved pegaptanib sodium. Pegaptanib
More informationEfficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema
111 ORIGINAL Efficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema Toshihiko Nagasawa, Takeshi Naito, Shingo Matsushita, Hiroyuki Sato, Takashi Katome, and
More informationRisk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical setting
Korb et al. BMC Ophthalmology 2013, 13:84 RESEARCH ARTICLE Open Access Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical
More informationRetinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related macular degeneration.
Thomas Jefferson University Jefferson Digital Commons Wills Eye Institute Papers Wills Eye Institute 4-1-2008 Retinal pigment epithelial tears after intravitreal bevacizumab injection for exudative age-related
More informationA prospective nonrandomized clinical study on exudative age related macular degeneration
Original Article A prospective nonrandomized clinical study on exudative age related macular degeneration Ayakutty Muni Raja, Siddharam Janti, Charanya Chendilnathan, Adnan Matheen Department of Ophthalmology,
More informationMacular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Glenn J. Jaffe, MD, 1 Daniel F. Martin, MD, 2 Cynthia A. Toth, MD, 1 Ebenezer Daniel, MPH, PhD,
More informationRetinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why?
Original Article Retinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why? Dr Sreelekha S. MS, DNB, DO, FRCS, Dr Manoj Soman DNB, FICO, FRCS, Dr. Unni Nair MS, FRCS, Dr. Ruminder
More informationRETINAL VENOUS OCCLUSIVE DISEASE IS PROBABLY
Clinical, Anatomic, and Electrophysiologic Evaluation Following Intravitreal Bevacizumab for Macular Edema in Retinal Vein Occlusion SIVAKAMI A. PAI, ROHIT SHETTY, PRIYA B. VIJAYAN, VENKATASUBRAMANIAM
More informationInternational Journal of Basic and Applied Physiology
Multifocal Electroretinography in Assessment Of Diseases Of Posterior Pole Of Retina JagdeepKaur S. Dani*, Mitesh M. Sinha**, Archana H. Patel**, Anju B. Mehta ***, Geeta B. Nair**** *Associate Professor,
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 9.03.20 Intraocular Radiation Therapy for Age-Related Macular Degeneration Photodynamic Therapy for Choroidal
More informationRetina Conference. Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014
Retina Conference Janelle Fassbender, MD, PhD University of Louisville Department of Ophthalmology and Visual Sciences 09/04/2014 Subjective CC/HPI: 64 year old Caucasian female referred by outside ophthalmologist
More informationAGE-RELATED MACULAR DEGENERATION (AMD) IS A
Intravitreal Bevacizumab for the Management of Choroidal Neovascularization in Age-related Macular Degeneration ZIAD F. BASHSHUR, MD, ALI BAZARBACHI, MD, ALEXANDRE SCHAKAL, MD, ZEINA A. HADDAD, MD, CHRISTELLE
More informationIntravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion
ORIGINAL RESEARCH Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to retinal vein occlusion Juan Carlos Mesa Gutiérrez Luis Arias Barquet Josep Maria Caminal Mitjana Sergi
More informationSystemic bevacizumab (Avastin) therapy for exudative neovascular age-related macular degeneration. The BEAT-AMD-Study
1 Department of Ophthalmology, The Ludwig Boltzmann Institute for Retinology and Biomicroscopic Lasersurgery, Rudolf Foundation Clinic, Vienna, Austria; 2 Department of Internal Medicine, Oncology, Rudolf
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationPhotodynamic Therapy for Choroidal Neovascularization
Photodynamic Therapy for Choroidal Neovascularization Policy Number: 9.03.08 Last Review: 10/2014 Origination: 10/2000 Next Review: 10/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationEFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY
EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road
More informationHHS Public Access Author manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2016 January 14.
High-Speed Ultrahigh-Resolution OCT of Bruch s Membrane in Membranoproliferative Glomerulonephritis Type 2 Mehreen Adhi, MD, Sarah P. Read, MD, PhD, Jonathan J. Liu, PhD, James G. Fujimoto, PhD, and Jay
More informationAbstract Aims To analyse the histopathology of classic and occult choroidal neovascular membrane surgical specimens in age
Br J Ophthalmol 2000;84:239 243 239 ORIGINAL ARTICLES Clinical science Clinicopathological correlation in exudative age related macular degeneration: histological diverentiation between classic and occult
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationDigital Journal of Ophthalmology Digital Journal of Ophthalmology. Abstract
Original Articles Combined intravitreal ranibizumab and verteporfin photodynamic therapy versus ranibizumab alone for the treatment of age-related macular degeneration Rosalia Giustolisi, MD, Nicoletta
More informationAndrew J. Barkmeier, MD; Benjamin P. Nicholson, MA; Levent Akduman, MD
c l i n i c a l s c i e n c e Effectiveness of Laser Photocoagulation in Clinically Significant Macular Edema With Focal Versus Diffuse Parafoveal Thickening on Optical Coherence Tomography Andrew J. Barkmeier,
More informationInstudies of vascular endothelial growth factor
MONITORING THERAPEUTIC EFFICACY IN THE ANTI-VEGF ERA* SriniVas R. Sadda, MD ABSTRACT One of the most important questions with vascular endothelial growth factor (VEGF) inhibitors for age-related macular
More informationNIH Public Access Author Manuscript JAMA Ophthalmol. Author manuscript; available in PMC 2013 September 10.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Ophthalmol. 2013 May ; 131(5): 693 694. doi:10.1001/jamaophthalmol.2013.692. Effect of Intravitreous Anti Vascular Endothelial
More informationDepartment of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea
Department of Ophthalmology, Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea Purpose: To investigate the factors that affect final vision following photodynamic therapy
More informationPhotodynamic Therapy for Treatment of Subfoveal Choroidal Neovascularization in Exudative Age-Related Macular Degeneration
Clinical Medicine Journal Vol. 4, No. 4, 2018, pp. 60-66 http://www.aiscience.org/journal/cmj ISSN: 2381-7631 (Print); ISSN: 2381-764X (Online) Photodynamic Therapy for Treatment of Subfoveal Choroidal
More informationEffectiveness of Ranibizumab for Neovascular Age-related Macular Degeneration using Clinician Determined Retreatment Strategy
Effectiveness of Ranibizumab for Neovascular Age-related Macular Degeneration using Clinician Determined Retreatment Strategy Anupma Kumar, Jayashree N Sahni, Alexandros N Stangos, Claudio Campa, Simon
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationCENTRAL SEROUS CHORIORETINOPATHY (CSC) IS
Association Between the Efficacy of Half-Dose Photodynamic Therapy With Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy MASSIMO
More informationFive-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration: Real Life Clinical Experience
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2017;31(5):424-430 https://doi.org/10.3341/kjo.2016.0125 Original Article Five-year Outcomes of Ranibizumab in Neovascular Age-related Macular Degeneration:
More informationDepartment of Ophthalmology, Kim s Eye Hospital, Konyang University College of Medicine, Seoul, Korea 2
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2015;29(5):315-324 http://dx.doi.org/10.3341/kjo.2015.29.5.315 Original Article Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related
More informationSubgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration
Subgroup Analysis of the MARINA Study of in Neovascular Age-Related Macular Degeneration David S. Boyer, MD, 1 Andrew N. Antoszyk, MD, 2 Carl C. Awh, MD, 3 Robert B. Bhisitkul, MD, PhD, 4 Howard Shapiro,
More informationThese issues are covered in more detail below.
26.3.07 Comments from Novartis on the Assessment Report for the Health Technology Appraisal of Pegaptinib and Ranibizumab for the treatment of age-related macular degeneration In general we feel that the
More informationAssessment of macular function by multifocal electroretinogram before and after macular hole surgery
420 Department of Ophthalmology, Gunma University School of Medicine, Japan Y-J Si S Kishi K Aoyagi Correspondence to: Ying-Jie Si, MD, Department of Ophthalmology, Gunma University School of Medicine,
More informationIntravitreal Injection of Ranibizumab for Recovery of Macular Function in Eyes With Subfoveal Polypoidal Choroidal Vasculopathy
Retina Intravitreal Injection of Ranibizumab for Recovery of Macular Function in Eyes With Subfoveal Polypoidal Choroidal Vasculopathy Ken Ogino, Akitaka Tsujikawa, Kenji Yamashiro, Sotaro Ooto, Akio Oishi,
More informationDescription. Section: Other Effective Date: July 15, Subsection: Vision Original Policy Date: December 7, 2011 Subject: Page: 1 of 23
Last Review Status/Date: June 2015 Page: 1 of 23 Description Photodynamic therapy (PDT) is a treatment modality designed to selectively occlude ocular choroidal neovascular tissue. The therapy is a 2-step
More informationOCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes
Doc Ophthalmol (2008) 116:159 164 DOI 10.1007/s10633-008-9113-1 CASE REPORT OCT and muti-focal ERG findings in spontaneous closure of bilateral traumatic macular holes Hongling Chen Æ Mingzhi Zhang Æ Shizhou
More informationDespite our growing knowledge of the
OVERVIEW OF AVAILABLE TREATMENTS FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION * Carl D. Regillo, MD ABSTRACT Although potential treatments for neovascular age-related macular degeneration represent
More informationElectrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema
Doc Ophthalmol (2008) 116:129 135 DOI 10.1007/s10633-007-9090-9 ORIGINAL RESEARCH ARTICLE Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationNEOVASCULAR AGE-RELATED MACULAR DEGENERation
Randomized, Double-Masked, -Controlled Trial of Ranibizumab for Neovascular Age-Related Macular Degeneration: PIER Study Year 2 PREMA ABRAHAM, HUIBIN YUE, AND LAURA WILSON PURPOSE: To evaluate efficacy
More informationUse of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes
Use of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes Daniel E. Charles, MD, Martin Charles, MD, Gisela Jelusich,
More informationIQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy Fawwaz Al Mamoori* Medical Retina Department, Eye Specialty Hospital,
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationCitation. As Published Publisher. Version
Effect of Intravitreous Anti Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Neovascular Age-Related Macular Degeneration Using Spectral-Domain The MIT Faculty has made this article
More informationEPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy
EPIRETINAL MEMBRANES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION Effect on Outcomes of Anti-vascular Endothelial Growth Factor Therapy EMINE ESRA KARACA, MD,* BURÇIN KEPEZ YILDIZ, MD, MEHMET ÖZGÜR
More informationStabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses
Graefe s Arch Clin Exp Ophthalmol (2004) 242:368 376 CLINICAL INVESTIGATION DOI 10.1007/s00417-003-0844-0 Rufino M. Silva José R. Faria de Abreu António Travassos José G. Cunha-Vaz Stabilization of visual
More informationNIH Public Access Author Manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2014 June 24.
NIH Public Access Author Manuscript Published in final edited form as: Ophthalmic Surg Lasers Imaging Retina. 2014 ; 45(1): 32 37. doi:10.3928/23258160-20131220-04. Analysis of the Short Term Change in
More information연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과
연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과 40 Table. Clinical characteristics and results of patients undergoing photodynamic therapy for retinal angiomatous proliferation Patients No. Age/ sex Eye
More informationAnti-VEGF drugs & CATT Results. in AMD. Apollo Hospitals, Hyderabad. Mallika Goyal, MD
Anti-VEGF drugs & CATT Results in AMD Mallika Goyal, MD Apollo Hospitals, Hyderabad Vascular Endothelial Growth Factor Napoleone Ferrara at Genentech 1989 identified & cloned the gene Protein that causes
More informationMichael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015
Michael P. Blair, MD Retina Consultants, Ltd Libertyville/Des Plaines, Illinois Clinical Associate University of Chicago 17 October 2015 So What Parts of the Eye Retina are Affected by VHL Neural tissue
More informationR&M Solutions
Mohamed Hosny El-Bradey, MD., Assistant Professor of Ophthalmology, Tanta University. Wael El Haig, MD., Professor of Ophthalmology. Zagazeeg University. 1 Myopic CNV is considered the most common vision
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationManagement of Acute Submacular Hemorrhage with Intravitreal Injection of Tenecteplase, Anti-vascular Endothelial Growth Factor and Gas
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2016;30(3):192-197 http://dx.doi.org/10.3341/kjo.2016.30.3.192 Original Article Management of Acute Submacular Hemorrhage with Intravitreal Injection
More informationWe know diabetes is a common and growing problem as well as the leading cause
ebook A GAME-CHANGER IN DIABETIC RETINOPATHY Early diagnosis and management guidance using objective, functional vision testing. by STEVEN M. SILVERSTEIN, MD We know diabetes is a common and growing problem
More informationMONTHLY ADMINISTERED INTRAVITREOUS PHARmacotherapy
Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab ALEXANDROS N. STANGOS, JAGDEEP SINGH GANDHI, JAYASHREE NAIR-SAHNI, HEINRICH HEIMANN,
More informationSchatz, Patrik; Skarin, Angelika; Lavaque, Alejandro J; Lima, Luiz H; Arevalo, Jose Fernando
Preservation of macular structure and function after intravitreal aflibercept for choroidal neovascularization associated with serpiginous choroiditis. Schatz, Patrik; Skarin, Angelika; Lavaque, Alejandro
More informationOptical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis
Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis G Pron August 2014 Ontario Health Technology Assessment Series; Vol. 14:
More informationDOME SHAPED MACULOPATHY. Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος
DOME SHAPED MACULOPATHY Ιωάννης Ν. Βαγγελόπουλος Χειρ. Οφθαλμίατρος - Βόλος DOME SHAPED MACULOPATHY-DEFINITIONS The entity Dome Shaped Macula ( DSM ) was first described by Gaucher and associates in 2008
More informationAn atypical case of choroidal neovascularization associated with pseudoxanthoma elasticum treated with intravitreal bevacizumab: a case report
Karampelas et al. BMC Research Notes 2013, 6:530 CASE REPORT Open Access An atypical case of choroidal neovascularization associated with pseudoxanthoma elasticum treated with intravitreal bevacizumab:
More informationVERTEPORFIN IN PHOTODYNAMIC THERAPY STUDY GROUP
Verteporfin Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration: Two-year Results of a Randomized Clinical Trial Including Lesions With Occult With No Classic Choroidal
More informationAngiogenesis and Role of Anti-VEGF Therapy
Review Article Angiogenesis and Role of Anti-VEGF Therapy P.S. Mahar, Azfar N. Hanfi, Aimal Khan Pak J Ophthalmol 2009, Vol. 25 No. 3.....................................................................................................
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationANTIVASCULAR ENDOTHELIAL GROWTH FACTOR
THE ROLE OF RANIBIZUMAB * Michael L. Klein, MD ABSTRACT The positive 1-year results of ranibizumab trials reported at the 23rd Annual Meeting of the American Society of Retina Specialists have generated
More informationThe limited number of currently approved
CLINICAL TRIALS OF VERTEPORFIN AND PEGAPTANIB: WHAT ARE THE RESULTS? * William F. Mieler, MD ABSTRACT Currently available treatment options for the management of choroidal neovascularization (CNV) in age-related
More informationClinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic Syndrome
Hindawi Publishing Corporation Journal of Ophthalmology Volume 215, Article ID 62372, 5 pages http://dx.doi.org/1.1155/215/62372 Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic
More informationOptical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP
Optical Coherence Tomography in Diabetic Retinopathy Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP Content OCT imaging Retinal layers OCT features in Diabetes Some NON DR features
More informationNoninvasive cross-sectional imaging of the retina
IDENTIFICATION OF FLUID ON OPTICAL COHERENCE TOMOGRAPHY BY TREATING OPHTHALMOLOGISTS VERSUS A READING CENTER IN THE COMPARISON OF AGE-RELATED MACULAR DEGENERATION TREATMENTS TRIALS CYNTHIA A. TOTH, MD,*
More informationRanibizumab and pegaptanib for the treatment of agerelated macular degeneration
Ranibizumab and pegaptanib for the treatment of agerelated Issued: August 2008 last modified: May 2012 guidance.nice.org.uk/ta155 NHS Evidence has accredited the process used by the Centre for Health Technology
More informationCombined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in two cases
Kodama et al. BMC Ophthalmology 2014, 14:36 CASE REPORT Open Access Combined treatment for Coats disease: retinal laser photocoagulation combined with intravitreal bevacizumab injection was effective in
More informationCorinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist
Corinne GONZALEZ Ophthalmology (MD, Ph.D ) Retinal Medical Specialist PRESENT PROFESSIONAL POSITION OPHTALMOLOGIST DOCTOR, Private practice Retinal medical Specialist, DMLA in particular Installation year
More informationChoroidal neovascularization (CNV) secondary to age-related
Retina Multifocal Pupillography Identifies Ranibizumab-Induced Changes in Retinal Function for Exudative Age-Related Macular Degeneration Faran Sabeti, 1 Ted Maddess, 1 Rohan W. Essex, 1,2 and Andrew C.
More informationCan intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?
European Journal of Ophthalmology / Vol. 18 no. 4, 2008 / pp. 591-594 Can intravitreal tissue plasminogen activator and SF6 gas facilitate management of macular degeneration with photodynamic therapy?
More informationAGE-RELATED MACULAR DEGENERATION IS THE LEADing
Photodynamic Therapy for Age-related Macular Degeneration in a Clinical Setting: Visual Results and Angiographic Patterns RUTH AXER-SIEGEL, MD, RITA EHRLICH, MD, YUVAL YASSUR, MD, IRIT ROSENBLATT, MD,
More informationOCT Assessment of the Vitreoretinal Relationship in CSME
December 2007 Sonia Rani John et al. - IFIS 375 ORIGINAL ARTICLE OCT Assessment of the Vitreoretinal Relationship in CSME Dr. Manoj S. DNB FRCS, Dr. Unnikrishnan Nair MS DO FRCS, Dr. Gargi Sathish MS Introduction
More informationOptical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to
More informationLong-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized
More informationI n the Western world, age related macular degeneration
207 SCIENTIFIC REPORT Clinicopathological findings of choroidal neovascularisation following verteporfin photodynamic therapy F Gelisken, B A Lafaut, W Inhoffen, M Voelker, S Grisanti, K U Bartz-Schmidt...
More informationPrevention and treatment of agerelated macular degeneration
THERAPY REVIEW Prevention and treatment of agerelated macular degeneration SARAH HORTON AND CATHERINE GULY Age-related macular degeneration (AMD) is a common cause of visual loss in older people and GPs
More informationRanibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
and for Treatment of Neovascular Age-related Macular Degeneration Two-Year Results Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group* Writing Committee: Daniel F. Martin,
More informationMeasurement of Subfoveal Choroidal Thickness Using Spectral Domain Optical Coherence Tomography
c l i n i c a l s c i e n c e Measurement of Subfoveal Choroidal Thickness Using Spectral Domain Optical Coherence Tomography Emily A. McCourt, MD; Brian C. Cadena, PhD; Cullen J. Barnett, CRA; Antonio
More informationThe effect of intravitreal bevacizumab in a rare case of retinal dystrophy with secondary cystoid macular edema
Romanian Journal of Ophthalmology, Volume 61, Issue 2, April-June 2017. pp:123-127 CASE REPORT The effect of intravitreal bevacizumab in a rare case of retinal dystrophy with secondary cystoid macular
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationRetinal Complications of Obstructive Sleep Apnea A Growing Concern!
Retinal Complications of Obstructive Sleep Apnea A Growing Concern! Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 6.01.10 Stereotactic Radiosurgery and Stereotactic Body Radiotherapy 8.01.10 Charged-Particle (Proton
More informationOCT Angiography in Primary Eye Care
OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central
More informationEfficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia
DOI: 10.4274/tjo.04874 Turk J Ophthalmol 2017;47:144-148 Original Article Efficacy of Intravitreal Bevacizumab in Treatment of Proliferative Type 2 Idiopathic Juxtafoveal Telangiectasia Ökkeş Baz, İhsan
More informationClinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
Ophthalmology Volume 12, Article ID 69641, 8 pages doi:1.1155/12/69641 Clinical Study Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular
More informationAuthors. Introduction. Introduction. Materials and Methods. Objective 10/27/2015
Idiopathic Polypoidal Choroidal Vasculopathy (IPCV) in Thai Population Presenting with Choroidal Neovascularization (CNV) A multicenter study Authors Yonrawee Piyacomn 1, Chavakij Bhoomibunchoo 1, Yosanan
More informationevaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography
evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography Dr. Mahmoud Alaa Abouhusssein, FRCO Lecturer of ophthalmology, Alexandria university Dr. Amir Ramadan Gomaa, MD
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Intraocular Radiation Therapy for Age-Related Macular Degeneration Policy Number: 9.03.20 Last Review: 9/2014 Origination: 9/2008 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationA Comparative Study of Age Related Macular Degeneration In Relation To SD-OCTand Fundus Photography.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 11 Ver. III (Nov. 2015), PP 33-37 www.iosrjournals.org A Comparative Study of Age Related Macular
More informationTESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN) ROBERTA P. A. MANZANO, MD, GHOLAM A. PEYMAN, MD, PALWASHA KHAN, MD, MUHAMET KIVILCIM, MD Purpose: To evaluate the retinal toxicity of varying doses
More informationMEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR EFFECTIVE DATE: 07/20/00 SUBFOVEAL CHOROIDAL NEOVASCULARIZATION
MEDICAL POLICY SUBJECT: PHOTODYNAMIC THERAPY FOR PAGE: 1 OF: 8 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More information